QH-II-66: Difference between revisions
CSV import |
CSV import |
||
| Line 32: | Line 32: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:QH-II-66.svg|QH-II-66 | |||
File:Qhii663d.png|QH-II-66 | |||
</gallery> | |||
Latest revision as of 01:25, 20 February 2025
QH-II-66 is a drug that belongs to the benzodiazepine class of medications. It is a sedative and anxiolytic drug that was developed by the China-based company, Qihuang Pharmaceutical.
History[edit]
QH-II-66 was first synthesized in the late 20th century by Qihuang Pharmaceutical. The drug was developed as part of a larger effort to create new benzodiazepine derivatives with improved therapeutic properties.
Pharmacology[edit]
Like other benzodiazepines, QH-II-66 works by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor, resulting in sedative, sleep-inducing (hypnotic), anxiolytic (anti-anxiety), anticonvulsant, and muscle relaxant properties.
Medical Uses[edit]
QH-II-66 is primarily used for the treatment of anxiety disorders, insomnia, and seizure disorders. It may also be used as a premedication for medical or dental procedures.
Side Effects[edit]
Common side effects of QH-II-66 include drowsiness, dizziness, and loss of coordination. More serious side effects may include memory problems, depression, and addiction.
